Compare · ENOV vs ZBH
ENOV vs ZBH
Side-by-side comparison of Enovis Corporation (ENOV) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $16.88B, about 12.4x ENOV ($1.36B).
- Over the past year, ENOV is down 28.1% and ZBH is down 5.9% - ZBH leads by 22.2 points.
- ZBH has been more active in the news (15 items in the past 4 weeks vs 14 for ENOV).
- ZBH has more recent analyst coverage (25 ratings vs 19 for ENOV).
- Company
- Enovis Corporation
- Zimmer Biomet Holdings Inc.
- Price
- $23.67-0.42%
- $87.32+0.01%
- Market cap
- $1.36B
- $16.88B
- 1M return
- -13.20%
- +4.71%
- 1Y return
- -28.10%
- -5.94%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 14
- 15
- Recent ratings
- 19
- 25
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest ENOV
- Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
- Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)
- SEC Form SD filed by Enovis Corporation
- Director Shirley Brady was granted 9,346 shares, increasing direct ownership by 9% to 110,589 units (SEC Form 4)
- Director Lalor Angela S was granted 9,346 shares, increasing direct ownership by 42% to 31,486 units (SEC Form 4)
- Director Ortiz Christine was granted 9,346 shares, increasing direct ownership by 60% to 25,011 units (SEC Form 4)
- Director Bodem Barbara W. was granted 9,346 shares, increasing direct ownership by 63% to 24,201 units (SEC Form 4)
- Director Okala Philip was granted 9,346 shares, increasing direct ownership by 63% to 24,201 units (SEC Form 4)
- Director Wienbar Sharon L was granted 9,346 shares, increasing direct ownership by 29% to 41,946 units (SEC Form 4)
- Director Perfall A Clayton was granted 9,346 shares, increasing direct ownership by 21% to 54,190 units (SEC Form 4)
Latest ZBH
- SEC Form 4 filed by Officer Noor Jehanzeb
- Group President, Asia Pacific Yi Sang sold $413,216 worth of shares (5,000 units at $82.64), decreasing direct ownership by 16% to 27,251 units (SEC Form 4)
- Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Bernard Betsy J
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Shapiro Louis
- SEC Form 4 filed by Director Kurdikar Devdatt